New screening method may detect twice as many cases of ovarian cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers from University College London have developed a new screening tool that can detect twice as many women with ovarian cancer as standard approaches.
Specifically, the study showed that the new method, which detects changes in CA125 levels, could detect cancer in 86% of women with invasive epithelial ovarian cancer.
CA125 is a protein biomarker in the blood of women that has been linked to ovarian cancer. A statistical test then predicts the woman's risk of having ovarian cancer.
"CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time," said Professor Ian Jacobs, chief investigator of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), an co-inventor of the statistical approach.
"What's normal for one woman may not be so for another. It is the change in levels of this protein that's important. My hope is that when the results of UKCTOCS are available this approach will prove capable of detecting ovarian cancer early enough to save lives."
The study evaluated 46,237 women who were screened annually for ovarian cancer over a 14-year period.
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|